Zentalis (ZNTL) Q2 Loss Narrows 70%

Key Points

• GAAP earnings per share of $0.37 in Q2 2025 exceeded the expected loss of $(0.59).

• The cash balance stood at $303.4 million as of Q2 2025, supporting operations into late 2027 despite no revenue recognized.

• Research and development plus administrative expenses (GAAP) were cut by roughly 44.7% compared to Q2 2024.

• These 10 stocks could mint the next wave of millionaires ›

Zentalis Pharmaceuticals (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company focused on developing cancer therapies, released its second quarter earnings on August 6, 2025. The headline news was a much narrower net loss per share than forecast: it posted a GAAP EPS of $0.37 for Q2 2025, better than analyst projections of a $(0.59) loss. As in past periods, it reported no revenue. Zentalis extended its cash runway well into 2027. Overall, the period reflects tighter financial discipline and progress on restructuring, with investors waiting for critical clinical trial data.

Source: Analyst estimates for the quarter provided by FactSet.

Overview of Zentalis Pharmaceuticals

Zentalis Pharmaceuticals is a biotechnology company developing targeted therapies for cancer. Its main product candidate is azenosertib, a WEE1 inhibitor designed to treat certain hard-to-treat cancers.

As a clinical-stage biotech company, Zentalis does not have commercial products on the market yet. The company's recent strategy has focused on tightly managing costs, progressing with clinical studies for azenosertib, and ensuring it has a solid financial position to advance the DENALI clinical trial. Success for Zentalis depends on the safety and effectiveness of its main drug, its ability to move through regulatory hurdles, and ultimately bring a product to market.

Quarterly Developments and Financial Performance

During the quarter, the company sharply reduced operating expenses. Research and development costs (GAAP) fell to $27.6 million, a 43% reduction compared to Q2 2024, as Zentalis narrowed clinical spending, cut laboratory expenses, and saved on drug manufacturing. General and administrative expenses dropped 49.7% compared to Q2 2024, largely from reductions in jobs and consulting. No restructuring costs were recorded, following the completion of the company’s earlier strategic realignment.

Despite cost cuts, Zentalis did not recognize any revenue this quarter, consistent with past periods while it remains in the pre-commercial development phase. Earlier, Zentalis recorded nonrecurring license revenue from the Immunome antibody-drug conjugate transaction, but this quarter’s absence of revenue highlights continued reliance on funding and expense management until a product reaches market.

From a scientific and development perspective, Zentalis continued work on its main program, the azenosertib WEE1 inhibitor. The clinical update confirms ongoing patient enrollment in the pivotal DENALI trial for Cyclin E1-positive platinum-resistant ovarian cancer, but did not include new efficacy or safety results. The company’s CEO cited the substantial unmet need for these patients, highlighting that about half of the PROC (platinum-resistant ovarian cancer) population may benefit if the drug is approved. No new partnerships, commercial collaborations, or significant business development actions were announced in the quarter.

On the manufacturing side, drug manufacturing costs decreased by $3.4 million compared to the prior year—as shown by a $3.4 million decrease in manufacturing costs compared to Q2 2024. The restructuring process is now finished, and Zentalis expects no further nonrecurring expenses related to it. The cash balance was $303.4 million as of June 30, 2025, down from $371.1 million as of December 31, 2024, but management reports this will support business operations through late 2027, based on the cash, cash equivalents, and marketable securities position as of June 30, 2025, which is after expected top-line results from the ongoing clinical study.

Looking Ahead

Zentalis leadership did not provide formal financial guidance for future quarters or the full fiscal year. The company stated only that its cash, cash equivalents, and marketable securities as of June 30, 2025, are expected to fund operations into late 2027, by which point it expects DENALI Part 2 data to be available by year-end 2026.

Investors will continue to watch for updates on the pivotal trial, potential regulatory filings, and any material news around azenosertib. Key issues to monitor include clinical progress, timeline clarity for top-line data, and any future collaboration or financing moves.

Revenue and net income presented using U.S. generally accepted accounting principles (GAAP) unless otherwise noted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,026%* — a market-crushing outperformance compared to 180% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of August 4, 2025

JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.